Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

NCT02667743 is registered in ClinicalTrials.gov with Shanghai Yizhong Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02667743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02667743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
Lead sponsor
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2015
Completion date
December 31, 2021
Enrollment
454 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer(nsclc)